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Edited by Veli-Pekka LehtoAbstract Deleted in liver cancer 2 (DLC2) is a candidate tumor
suppressor frequently found to be deleted in hepatocellular carci-
noma. In this study, we determined the subcellular localization of
DLC2. Co-localization and biochemical fractionation studies re-
vealed that DLC2 localized to mitochondria. In addition, the
DLC2-containing cytoplasmic speckles were in proximity to li-
pid droplets. A DLC2 mutant containing the steroidogenic acute
regulatory protein-related lipid transfer (START) domain only
showed a localization pattern identical to that of DLC2. Taken
together, we have provided the ﬁrst evidence for mitochondrial
localization of DLC2 through the START domain. These ﬁnd-
ings might have implications in liver physiology and carcinogen-
esis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepatocellular carcinoma1. Introduction
Hepatocellular carcinoma (HCC) is one leading cause of
cancer death in Asia and in the World [1]. Hepatocarcinogen-
esis is a multistage process, in which chromosomal aberrations
frequently occur on chromosome 1p, 8p, 13q, 16p and 17p,
leading to alteration of genes that govern cell growth and tu-
mor suppression [2]. Well-known tumor suppressor genes in-
volved in HCC include p53, c-myc, p16INK4 and b-catenin
[3]. However, HCC is genetically heterogeneous and additional
tumor suppressors critical in HCC remain to be characterized.
Deleted in liver cancer 2 (DLC2), also known as steroido-
genic acute regulatory protein-related lipid transfer (START)
domain containing protein 13 (STARD13), is a novel growth
suppressor protein we have identiﬁed [4]. DLC2 is a paralog
of DLC1, a known tumor suppressor gene at chromosomeAbbreviations: DLC2, deleted in liver cancer 2; GAP, GTPase activa-
ting protein; HCC, hepatocellular carcinoma; PBS, phosphate buﬀered
saline; SAM, sterile a-motif; SRE, serum response element; StAR,
steroidogenic acute regulatory protein; START, steroidogenic acute
regulatory protein-related lipid transfer; TRITC, tetramethylrhod-
amine isothiocyanate
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DLC2 proteins share 51% identity and 64% similarity at the le-
vel of their amino acid sequences. Interestingly, DLC2 local-
izes to chromosome 13q12.3, which is also frequently found
to be deleted in HCC. Existing evidence from analysis of
DLC2 DNA and mRNA suggests that DLC2 is underex-
pressed in a signiﬁcant number of HCC cases. Sequence anal-
ysis indicates that DLC2 is a multidomain protein containing
sterile a-motif (SAM), GTPase-activating protein (GAP) and
START domains [4]. All three domains are also highly con-
served in DLC1, since 76%, 74% and 60%, respectively, of their
amino acid residues are identical.
We have previously shown that DLC2 protein has GAP
activity speciﬁc for small GTPases RhoA and Cdc42 [4]. Thus,
DLC2 should stimulate the hydrolysis of GTP in those GTP-
ases, turning them into inactive GDP-bound form and shutting
down the signal transduction [8,9]. Consistent with this, the
introduction of human DLC2 into mouse ﬁbroblasts sup-
presses Ras signaling and Ras-induced cellular transformation
in a GAP-dependent manner. Those ﬁndings suggest a role for
DLC2 in growth suppression and carcinogenesis [4].
While the RhoGAP activity of DLC2 has been characterized
[4], the function of its START domain remains to be under-
stood. The START domain has been found in a large variety
of proteins with diﬀerent functions [10,11]. It is a well-con-
served lipid-binding domain widely found among lower pro-
karyotes, archaea and multicellular eukaryotes [12]. Among
known START containing proteins in mammals, steroidogenic
acute regulatory protein (StAR), metastatic lymph node-64
(MLN64) and phosphatidylcholine transfer protein (PC-TP)
are better characterized members, with their protein structure
resolved using X-ray crystallography and their lipid ligands
identiﬁed [12]. StAR and MLN64 speciﬁcally bind cholesterol;
for PC-TP, the lipid it binds is phosphatidylcholine [13]. StAR
is also known to stimulate the intake of cholesterol from cyto-
sol into mitochondria which initiates the production of sterol
in steroidogenesis [14]. In this regard, characterization of the
START domain in DLC2 will provide new avenues to func-
tional analysis of DLC2, DLC1 and related proteins. In partic-
ular, it will be of great interest to see whether the START
domain would have an impact on the subcellular localization
of DLC2 through interaction with lipids presented in the bio-
logical membranes.
In this study, we sought to determine the subcellular locali-
zation patterns of DLC2 in cultured hepatoma cells using
confocal immunoﬂuorescence microscopy. Because otherblished by Elsevier B.V. All rights reserved.
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critical role in lipid transport to mitochondria [14], we asked
particularly whether DLC2 might associate with mitochon-
dria. We also examined the role of the START domain in this
function. Additionally, we also investigated the localization of
DLC2 in relation to lipid droplets.2. Materials and methods
2.1. Plasmids
Reporter plasmid pSRE-Luc, in which the expression of ﬁreﬂy lucif-
erase is under the control of multiple copies of serum response ele-
ments (SREs; AGGATGTCCATATTAGGACATCT, the consensus
sequences are bold), was purchased from Stratagene. Expression vec-
tor for dominant active Ras mutant RasV12 has been described [4].
Plasmids pCMV-DLC2, pCMV-DSAM, pCMV-START, pCMV-
DSTART and pCMV-dGAP are based on expression vector pCMV-
tag3C (Stratagene). They contained, respectively, the full-length
DLC2, truncated DLC2 mutant DLC2-DSAM (119–1113 amino acid
residues) without the SAM domain, truncated mutant DLC2-START
carrying only the START domain (906–1113 residues) of DLC2, trun-
cated mutant DLC2-DSTART lacking the START domain (908–1113
residues) only, and R699A point mutant DLC2-dGAP with a defective
RhoGAP domain [4]. Notably, a Myc epitope has added to the N-ter-
minal of DLC2 and DLC2-DSAM, while the other mutants contain an
N-terminal V5 tag.
2.2. Cell culture and transfection
Human hepatoma cell line Huh-7 [15] was obtained from Japanese
Collection of Research Bioresources. Huh-7 cells were maintained in
Dulbecco’s Modiﬁed Eagle’s Medium supplemented with 10% fetal bo-
vine serum, 1.5 g/L sodium bicarbonate and antibiotics. Cultured cells
were transfected using GeneJuice reagents (Novagen).
2.3. Luciferase assay
Dual-luciferase assay was performed with extracts of transiently
transfected Huh-7 cells as previously described [4,16]. For this assay,
both ﬁreﬂy and Renilla (sea pansy) luciferase reporter enzymes were
expressed simultaneously in the cell. The activity of the co-transfected
Renilla reporter gene provides an internal control that can be used for
normalization of the ﬁreﬂy reporter activity recovered, thereby elimi-
nating the diﬀerences in cell viability and transfection eﬃciency.
2.4. Western blotting
Western blotting was carried out as previously described [17].
Brieﬂy, protein extracts prepared from transfected and untransfected
Huh-7 cells were solubilized with SDS gel loading buﬀer (60 mM Tris,
2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.1% bromophenol
blue), separated by SDS–PAGE, and then electroblotted onto Immo-
bilon-P PVDF-type membranes (Millipore) using a semi-dry blotting
apparatus (Hoefer SemiPhor). Blots were blocked with 5% skim milk,
followed by incubation with a monoclonal antibody against Myc tag
(Amersham) or against V5 tag (Invitrogen). Blots were then incubated
with goat anti-mouse secondary antibody conjugated to horseradish
peroxidase (Amersham) and visualized by enhanced chemilumines-
cence (ECL, Amersham).
Mitochondria of Huh-7 hepatoma cells were prepared by using
mitochondria isolation kit (Sigma). Rabbit polyclonal antibodies
against human peroxiredoxin-I or against human peroxiredoxin-III
were purchased from Lab Frontier (Seoul, Korea). Secondary anti-
body was goat anti-rabbit antibody conjugated to horseradish peroxi-
dase (Amersham).
2.5. Confocal microscopy
Laser-scanning confocal immunoﬂuorescence microscopy was per-
formed as previously described [18,19]. Brieﬂy, monolayer Huh-7 cells
were grown overnight on coverslips put in six-well plate. Transfected
cells were washed with phosphate buﬀered saline (PBS) and ﬁxed with
freshly prepared 4% paraformaldehyde, buﬀered in PBS, for 10 min at
room temperature. Membrane on ﬁxed cells was permeabilized with0.1% Triton-X100/PBS for 10 min at room temperature. To minimize
non-speciﬁc staining, a 3% bovine serum albumin in PBS was used to
incubate the treated cells for 30 min at room temperature. Incubation
with primary antibodies (rabbit polyclonal anti-Myc antibody from
Santa Cruz and mouse monoclonal anti-V5 from Invitrogen) was typ-
ically for 8 h at 40 C, and with secondary antibodies (ﬂuorescein-con-
jugated donkey polyclonal anti-rabbit IgG from Chemicon and
ﬂuorescein-conjugated rat polyclonal anti-mouse IgG from Zymax),
it was typically for 2 h at room temperature. Mitochondria marker
Mitotracker Red CMXRos (Molecular Probes) was added to culture
medium 10 min prior to cell harvest to maximize staining and minimize
background. Lipid stain Nile red (Sigma) was applied and incubated at
room temperature for 30 more minutes. The coverslips were washes for
several times with PBS and then mounted on slides with Mowiol
mounting medium (Mowiol 4-88 from Sigma, prepared in glycerol
and Tris–Cl, pH 8.5). Antifade reagent 1,4-diazabicyclo-[2.2.2]octane
can be added to the prepared Mowiol solution to prevent photobleach-
ing of the green signal. Double labeling was achieved by using diﬀerent
ﬂuorophores (e.g., ﬂuorescein and tetramethylrhodamine isothiocya-
nate (TRITC)). Images were mostly captured at 63· magniﬁcation
with the help of the LaserSharp software. Some images were further
enlarged using Adobe Photoshop.3. Results
3.1. Expression of DLC2 in cultured hepatoma cells
We have previously demonstrated DLC2 to be a novel Rho-
GAP protein that has growth suppressor activity and is fre-
quently underexpressed in HCC tissues and cells [4]. In that
published work, we have not been able to express full-length
DLC2 in cultured HepG2 and Hep3B hepatoma cells, proba-
bly due to the cytotoxic eﬀects induced by ectopic expression.
Further optimization of the conditions for transfection led to
successful expression of Myc-tagged DLC2 at low level in hu-
man Huh-7 hepatoma cells as detected by Western blotting
(Fig. 1A, lane 1 compared to lane 2). A V5-tagged DLC2 mu-
tant containing the START domain only (DLC2-START or
START) was also eﬃciently expressed in Huh-7, Hep3B and
other cell lines without inducing cytotoxicity (Fig. 1A, lane 3
compared to lane 4).
In order to obtain a quick answer on the functionality of
DLC2 and DLC2-START in cultured cells, we compared their
abilities to regulate cell signaling. If DLC2 is functional, it
should have an impact on Ras signaling, because DLC2 is a
GAP protein speciﬁc for RhoA and Cdc42 that are activated
by Ras [20,21]. Previously, we have shown that a truncated
version of DLC2 (i.e., DLC2-GAP) is capable of suppressing
Ras-induced activation of SRE and Ras-dependent transfor-
mation of NIH3T3 cells [4]. SRE is an important eﬀector of
RhoA and Cdc42 [22] and can be activated potently by
RasV12, a constitutively active mutant of Ras [23]. In keeping
with this, we noted that RasV12 eﬃciently activated SRE-dri-
ven expression of luciferase reporter (Fig. 1B, compare column
2 to column 1). In this experimental setting, if DLC2 functions
as a RhoGAP protein intracellularly, it should inhibit the stim-
ulation of SRE by RasV12.
Indeed, we observed that DLC2, when expressed in Huh-7
cells, can signiﬁcantly reduce the activation of SRE-depen-
dent luciferase reporter expression by RasV12 (Fig. 1B, com-
pare column 3 to column 2). In contrast, DLC2-START is
unable to inhibit SRE activity (Fig. 1B, compare column 4
to column 3). These results provided the ﬁrst evidence that
DLC2 is functional in suppressing Ras signaling in mamma-
lian cells.
Fig. 1. Expression and activity of DLC2 in Huh-7 hepatoma cells. (A) Western blot analysis. Huh-7 cells were mock-transfected (lanes 2 and 4) or
transfected with an expression plasmid for Myc-tagged DLC2 (lane 1) or V5-tagged DLC2-START (lane 3). Equal amount (10 lg) of protein was
loaded onto each lane. The blots were probed with anti-Myc (lanes 1 and 2) or anti-V5 (lanes 3 and 4) antibody. DLC2 of >120 kDa and DLC2-
START of 27 kDa in size are indicated. Also shown are migration positions of molecular weight markers. (B) Suppression of Ras-induced activation
of SRE by DLC2. Huh-7 cells were transfected with pSRE-Luc alone (column 1), pSRE-Luc + RasV12 (column 2), pSRELuc + RasV12 + DLC2
(column 3) and pSRELuc + RasV12 + DLC2-START (column 4). Results are representative of three independent experiments and the error bars
indicate S.E. Luc activity: ﬁreﬂy luciferase activity in arbitrary units normalized to Renilla luciferase activity.
D.C.-H. Ng et al. / FEBS Letters 580 (2006) 191–198 1933.2. Subcellular localization of DLC2
Subcellular localization of a protein often provides critical
information for its function. In agreement with previous ﬁnd-
ings on rat DLC1/p122RhoGAP [24], the overexpression of
DLC2 by adding a higher concentration of expression plasmid
(1 lg/ml) in the transfection mixture caused substantial cell
death and detachment. This cytotoxicity is probably due to
the high RhoGAP activity of DLC2.
In order to achieve better expression of DLC2 in cultured
Huh-7 cells, we adjusted the conditions for transient transfec-
tion. This optimization, which involved a 10-fold reduction of
plasmid concentration to 0.1 lg/ml in the transfection mixture,
led to signiﬁcant reduction of cell death or detachment. Under
this condition, about 15% of the cells were normally transfec-
ted. All viable transfected cells showed expression of DLC2 in
the cytoplasm (Fig. 2, panels A–C). In particular, the DLC2-
speciﬁc signal was punctuate, suggesting that DLC2 was con-
centrated in cytoplasmic speckles (Fig. 2, panels A–C).
Notably, the localization patterns of full-length DLC2 and
DLC2 mutant DLC2-DSAM without the N-terminal SAM do-
main and DLC2-START were very similar (Fig. 2, compare
panels D–F to panels A–C). Thus, the N-terminal SAM do-
main is dispensable for DLC2 localization.
In addition to the catalytic GAP domain, DLC2 and DLC2-
DSAM also share a START domain that might have regula-tory function. Hence, we next addressed the question as to
whether the START domain is essential for the subcellular
localization of DLC2. The START domain is located at the
very end of DLC2, near the C terminal. Analysis of the amino
acid sequence has revealed no noticeable localization signal on
this portion of DLC2. However, the START domain is
thought to be lipophilic [14]. A mutant of DLC2 containing
the START domain alone, named DLC2-START, was con-
structed and expressed as a V5-tagged protein in Huh-7 cells
(Fig. 1A, lane 3). Under the confocal microscope, DLC2-
START was found to be in dotted form throughout the cyto-
sol, although some cells had DLC2-START protein aggregates
in the perinuclear region (Fig. 2, panels G–I). This localization
pattern of DLC2-START resembles that observed in cells
transfected with DLC2 and DLC2-DSAM (Fig. 2, compare
panels G–I to panels A–F). In another word, the START do-
main can suﬃciently target DLC2 to a particular intracellular
compartment. In further support of this role of DLC2-
START, a DLC2 mutant lacking the START domain only
(DLC2-DSTART) was found to distribute homogenously in
the cytoplasm (Fig. 2, panels J–L). In contrast, the R699A
point mutant of DLC2 with a defective RhoGAP domain
(DLC2-dGAP) and an intact START domain, which could
be expressed abundantly in various cell lines without inducing
cytotoxicity, localized to perinuclear speckles. The localization
Fig. 2. Subcellular localization of DLC2 and its mutants in Huh-7
cells. Huh-7 cells were transfected with 0.1 lg/ml of plasmid expressing
Myc- or V5-tagged DLC2 (panels A–C), DLC2-DSAM (D–F), DLC2-
START (G–I), DLC2-DSTART (J–L) or DLC2-dGAP (M–O). A
schematic diagram of the domain structure of DLC2 and its mutants is
also shown (P). Cells were stained for DLC2 with mouse monoclonal
anti-Myc (panels B and E) or anti-V5 (panels H, K and N). Nuclear
morphology was visualized by counterstaining with propidium iodide
(PI; panels A, D, G, J and M). The green (representing DLC2) and red
(representing PI) ﬂuorescent signals were merged by computer
assistance (panels C, F and I). The same ﬁelds of cells are shown in
panels A–C, D–F, G–I, J–L and M–O.
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dGAP were very similar.
Collectively, our data demonstrated for the ﬁrst time an
intracellular function of the START domain in DLC2.3.3. Mitochondrial localization of DLC2
As the subcellular localization of DLC2 holds the clues to its
function, it will be of great interest to deﬁne the identity of
these DLC2-containing speckles. In light of the facts that mito-
chondria are important in lipid metabolism [25] and that other
START domain proteins such as StAR play a role in lipid
transport into mitochondria [14], this organelle is one possible
target of DLC2. To study this possibility, a commercially
available chemical stain for mitochondria, known as Mito-
Tracker-TRITC [26], was used to co-stain Huh-7 cells transfec-
ted with either Myc-tagged DLC2 (Fig. 3) or V5-tagged
DLC2-START (data not shown).
Interestingly, a signiﬁcant portion of DLC2 co-localized
with mitochondria, as shown in Fig. 3 (see panel C for yel-
low patches indicating co-localization). Computer-assisted
analysis showed that the DLC2 staining overlapped that of
mitochondria perfectly. In fact, over 75% of the ﬁelds cap-
tured showed such co-localization of DLC2 and mitochon-
dria. Noteworthily, almost all DLC2 signals overlapped
those of mitochondria, but not all mitochondria were tar-
geted by DLC2.
The co-localization of DLC2 with mitochondria (Fig. 3,
panels A–C) and the similar localization patterns of DLC2
and DLC2-START (Fig. 2) strongly suggest that DLC2-
START would also localize to mitochondria. Indeed,
concentrated DLC2-START speckles co-stained with Mito-
Tracker-TRITC both in both Huh-7 and HeLa cells (Fig. 3,
panels D–I), indicating that the START domain targets
DLC2 to mitochondria.
To verify the mitochondrial localization of DLC2, biochem-
ical fractionation experiments were carried out. Mitochondria
were isolated from the lysate of Huh-7 cells transfected with
Myc-DLC2 and probed with an anti-Myc antibody (Fig. 4).
The Myc-tagged DLC2 protein was found both in the total cell
lysate and in the mitochondrial fraction (Fig. 4A, lanes 1 and
2). As a control, we also examined human peroxiredoxin-I and
peroxiredoxin-III, which are known to localize primarily to the
cytoplasm and mitochondria, respectively [18,27,28]. While
mitochondrial peroxiredoxin-III was found both in the total
cell lysate and in the mitochondria (Fig. 4C), cytoplasmic per-
oxiredoxin I was detected only in the total cell lysate, but not
the mitochondrial fraction (Fig. 4B, compare lane 1 to lane 2).
That is to say, the mitochondria prepared in our experiment
were not contaminated with the cytoplasmic fraction. Thus,
our results from biochemical fractionation conﬁrmed the mito-
chondrial localization of DLC2.
3.4. Localization of DLC2 in relation to lipid droplets
The START domain is thought to have lipid-binding activ-
ity [14]. To study the interaction of DLC2 with intracellular
lipids, we asked whether the DLC2-speciﬁc ﬂuorescent signals
would overlap with lipid-reactive dyes. It is well known that
intracellular lipids can be stained with various dyes such as
Nile red and Sudan III [29]. Hence, we co-stained lipid-rich
Huh-7 hepatoma cells for both DLC2-START and lipids using
an anti-Myc antibody and Nile red, respectively (Fig. 5).
DLC2-START was used in this experiment because the local-
ization patterns of DLC2 and DLC2-START are very similar
(Fig. 2).
As shown in Fig. 5, the speckles containing DLC2-START
localized around the lipid droplets stained by Nile red. Inter-
estingly, the two signals did not overlap substantially with each
Fig. 3. Mitochondrial localization of DLC2 and DLC2-START. Huh-7 cells were transfected with 0.1 lg/mL pCMV-DLC2 plasmid expressing
DLC2 (panels A–C). Huh-7 (panels D–F) or HeLa (panels G–I) cells were transfected with 0.5 lg/mL pCMV-START plasmid expressing DLC2-
START. Cells were then stained for DLC2 or DLC2-START with mouse monoclonal anti-Myc (panel B) or anti-V5 (panels E and H), and for
mitochondria with MitoTracker CMXRos conjugated to TRITC (Molecular Probes; panels A, D and G). The green (representing DLC2 or DLC2-
START) and red (representing mitochondria) ﬂuorescent signals were merged by computer assistance (panels C, F and I). Co-localization is in yellow
(highlighted with arrows). The same ﬁelds of cells are shown in panels A–C, D–F and G–I. Similar results were also obtained with DLC2-START in
NIH3T3 cells (data not shown).
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in proximity to the droplets of lipid (Fig. 5, panels C and F).
Thus, consistent with its putative lipid-binding or lipid-transfer
activity, the START domain of DLC2 likely serves a lipid-re-
lated function in the cell and it targets DLC2 to areas proximal
to the lipid droplets.4. Discussion
In this study, we determined the subcellular localization of
growth suppressor protein DLC2 in human Huh-7 hepatoma
cells using confocal immuno-ﬂuorescence microscopy. First
we performed Western blotting to verify the transient expres-
sion and functionality of full-length DLC2 in Huh-7 hepatoma
cells (Fig. 1). Then we deﬁned a novel pattern for DLC2 local-
ization and demonstrated the role of the START domain in
intracellular targeting of DLC2 (Fig. 2). We established that
DLC2 localized to mitochondria via the START domain (Figs.
3 and 4). Finally, we also documented that the DLC2-contain-
ing cytoplasmic speckles were in proximity to lipid droplets
(Fig. 5).
4.1. Function of START domain in DLC2
Our ﬁndings establish one function of the START domain in
targeting DLC2 to subcellular compartments overlapping with
mitochondria and proximal to the lipid droplets. This functionis consistent with the predicted lipid-binding or lipid-transfer
activity of the START domain [14,30]. Actually the START
domain in some other proteins might also play a similar role
in protein targeting by tethering to membrane or to other
START containing proteins [31]. Further investigation on
DLC2-START will provide additional insight into the cellular
function of DLC2 and related proteins. In this context, the
identiﬁcation of the lipid ligand of DLC2-START remains
an important task for the next stage of our investigation. In
addition, we will also investigate the relevance of this lipid-
binding activity to the predicted interaction with and regula-
tory role on phospholipase Cd1, which has been demonstrated
for rat DLC1 [32].
Other START domain proteins such as MLN64 are criti-
cally involved in carcinogenesis or metastasis [33]. The func-
tion of the START domain in protein targeting raises
another interesting question as to whether this domain is re-
quired for the growth suppressive activity of DLC2. It also
remains to be understood whether the START domain of
DLC2 might serve as a molecular switch to regulate Rho-
GAP activity upon binding with lipids. In this regard, Rho-
GAP protein p190 has previously been shown to be
regulated by phospholipids [34]. On the other hand, it is un-
clear whether the RhoGAP activity of DLC2 might have an
impact on the function of the START domain. All these
questions concerning the START domain of DLC2 warrant
further study.
Fig. 4. Detection of DLC2 in the mitochondrial fraction. Huh-7 cells
were transfected with an expression plasmid for Myc-tagged DLC2.
Biochemical fractionation was performed to isolate mitochondria.
Equal amounts (8 lg) of protein from total cell lysate (total; lane 1)
or from mitochondrial fraction (mito; lane 2) were loaded. The blots
were probed with anti-Myc (A), anti-Prx-I (B) or anti-Prx-III
antibody.
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with a recent study which has suggested that the START do-
main in DLC1 is functional [35]. While the START domains
in DLC2 and DLC1 are highly conserved, the subcellular
localization of DLC1 has not been extensively studied. Thus,
it will be of great interest to see whether the START domain
might also target DLC1 to mitochondria.Fig. 5. Subcellular localization of DLC2-START in relation to lipid droplet
V5-tagged DLC2-START. Cells were then stained for DLC2 with mouse mo
(panels A and D). The green (representing DLC2) and red (representing li
(panels C and F). Co-localization should be in yellow. The same ﬁelds of ce4.2. Mitochondrial localization of DLC2 in relation to lipid
droplets
Our ﬁndings that DLC2 localizes to cytoplasmic speckles
overlapping with mitochondria and proximal to lipid droplets
are consistent with recent results from proteomic analysis of
adipocytes, which reveal a close association of lipid droplets
with mitochondria [36].
Lipid droplets are a reservoir of lipids for the synthesis and
maintenance of membranes [36]. The mechanisms by which
lipids are transported into and out of lipid droplets are poorly
understood. Yet, various lipid metabolic enzymes have been
found in or around the lipid droplets. The appearance of
DLC2 in cytoplasmic speckles surrounding the lipid droplets
suggests that DLC2 might serve a lipid-related function.
Further characterization of the cellular function of DLC2 in
relation to lipid droplets requires the veriﬁcation of the lipid-
binding activity of DLC2 and the identiﬁcation of its lipid
ligand. Prototypic START domain proteins StAR and
MLN64 play a pivotal role in lipid transport into mitochon-
dria [14,37]. Particularly, StAR localizes to the mitochondria
and promotes the translocation of cholesterol from outer to in-
ner mitochondrial membranes [31]. The localization of DLC2
to mitochondria in tight association with lipid droplets impli-
cates a role of DLC2 in mitochondrial lipid transport. This no-
tion is further strengthened by a recent report on a ‘‘RhoGAP
encoded on chromosome 13q12’’, which turns out to be DLC2
[38]. In that study, the entire coding sequence of DLC2 was
used as bait in a yeast-2-hybrid screen and several interesting
proteins that potentially bind to DLC2 were identiﬁed. Among
those candidates, HMG-CoA reductase is more interesting
than others as it is involved in the energy pathway found in
mitochondria. HMG-CoA is the rate limiting enzyme in cho-
lesterol biosynthesis [39]. Since the START domain of DLC2
is actively targeted to the mitochondria, it is reasonable to
hypothesize that this START domain will indeed tether with
HMG-CoA in vivo and play a pivotal role in the lipid biosyn-
thesis pathway.s. Hepatoma Huh-7 cells were transfected with expression plasmid for
noclonal anti-V5 (panels B and E) and for lipid droplets with Nile red
pid droplets) ﬂuorescent signals were merged by computer assistance
lls are shown in panels A–C and D–F.
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[4]. The mitochondrial targeting of DLC2 raises the interesting
possibility that DLC2 might fulﬁll its growth suppressive func-
tion by regulating mitochondrial membrane permeability and
the mitochondrial pathway of apoptosis [40]. Thus, it will be
of interest to investigate whether DLC2 modulates cell survival
and how this modulation contributes to its eﬀects on cell pro-
liferation. In connection to this, the relationship between mito-
chondrial targeting of DLC2 and the induction of apoptosis
merits further investigations.
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